• Diagnosed with T2D greater than or equal to (≥) 180 days prior to the day of screening.

• Treatment with any of the following non-insulin glucose-lowering medication(s) or combination regimen(s) at the time of screening:

⁃ Metformin, Sulfonylureas, Meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, Thiazolidinediones, Alpha-glucosidase inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs), Oral or injectable glucagon-like peptide-1 (GLP-1) receptor agonists and Injectable dual glucose-dependent insulinotropic polypeptides (GIP) and GLP-1 receptor agonist.

• Need of intensification with basal insulin, as indicated at the discretion of the investigator.

• Recorded HbA1c value ≥7% within the last 90 days prior to randomization.